When was FYR Diagnostics founded?

FYR Diagnostics was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is FYR Diagnostics located?

FYR Diagnostics is headquartered in Missoula, United States.

How many employees does FYR Diagnostics have?

As of May 31, 2026, the latest employee count at FYR Diagnostics is 17.

Is FYR Diagnostics a funded company?

FYR Diagnostics is a funded company, having raised a total of $8M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 01, 2019.

When was the latest funding round of FYR Diagnostics?

FYR Diagnostics' latest funding was a $***** Series A round on Aug 02, 2024, with participation from 0 investor.

Where does FYR Diagnostics rank among its competitors?

FYR Diagnostics ranks 30th amongst 110 active competitors, of which 33 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of FYR Diagnostics?

FYR Diagnostics' top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

FYR Diagnostics - 2026 Company Profile, Funding & Competitors

Company Details

Provider of in-vitro diagnostic tests for the detection of diseases. The company develops a portfolio of biomarker detection technologies with a focus on nucleic acid amplification that enables the accelerated prediction, diagnosis, and management of human and agricultural diseases.

Key Metrics

Founded Year

2016

Location

Missoula, United States

Stage

Series A

Total Funding

$8M in 4 rounds

Latest Funding Round

Series A, Aug 02, 2024, $*****

Investors

Two Bear Capital & 3 more

Ranked

30^th among 110 active competitors

Employee Count

17 as on May 31, 2026

Similar Companies

Seer & 139 more

View FYR Diagnostics' full profile

FYR Diagnostics has raised a total funding of $8M over 4 rounds. Its first funding round was on Sep 01, 2019. FYR Diagnostics has 4 institutional investors.

Here is the list of recent funding rounds of FYR Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 02, 2024	9601148	Series A	9116387	5649272	9951813	1881471
Aug 15, 2021	2117310	Grant (prize money)	6891699	7953777	7218930	HHS
Dec 01, 2020	4527629	Grant (prize money)	1847586	9851684	1928725	America’s Seed Fund

Access funding benchmarks and valuations. Sign up today!

View details of FYR Diagnostics's funding rounds and investors

FYR Diagnostics' employee count trend

FYR Diagnostics has 17 employees as of May 26. Here is FYR Diagnostics's employee count trend over the years:

Employee count trend for FYR Diagnostics

Uncover FYR Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FYR Diagnostics include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of FYR Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 7 others	70/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Deep Track Capital, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	New Enterprise Associates, Bay City Capital ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	CICC, Guangzhou Yuexiu Industrial Investment Fund Management ... & 12 others	56/100
8th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, FNIH & 1 others	56/100
9th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
30th	FYR Diagnostics 2016, Missoula (United States), Series A	Provider of in-vitro diagnostic tests for the detection of diseases	$8M	Two Bear Capital, America’s Seed Fund & 2 others	40/100